REGN REGENERON PHARMACEUTICALS, INC.

Price Chart

Executive Summary

On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN). Citigroup cut from Buy to Neutral, slashed price target from $900 to $700, nearly in line with the current $698.25. Leerink Partners downgraded from Outperform to Market Perform with a $641 target, implying ~8% downside. Both firms have below-average track records on REGN (Citi 43% accuracy on 7 calls, Leerink 50% on 2 calls). Consensus remains strongly bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, with a mean price target of $875.31 (25.4% upside). EPS revision momentum is positive, with 15 upgrades vs 6 downgrades for the next quarter. Insider sales are small and routine; institutional activity is mixed (Two Sigma trimming but Norges Bank adding a $1B position). While the cluster downgrade signals near-term caution, the positive consensus and earnings momentum suggest the stock may find support near $700. The low accuracy of the downgrading firms reduces the significance of this action.

Impact Score

Consensus & Targets

Consensus is heavily bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, 8 Hold (21%), and 0 Sell. The average price target is $875.31 with a median of $882.5. The downgrades are contrarian to the consensus view, which sees 25.4% upside from current levels.

Mean price target $875.31, median $882.5, high $1057, low $730. Current price $698.25 implies 25.4% upside to mean. Citigroup's new $700 PT of $700 is below the consensus low of $730, and Leerink's $641 is even lower. Both new targets are well below the consensus mean of $875.31, reflecting a more pessimistic view than the average analyst.

Recent Analyst Activity

In the last 30 days, REGN has seen 0 upgrades and 2 downgrades (these). EPS revisions for the current quarter are positive: 15 upward vs 6 downward in 30 days, with consensus rising $12.30 to $13.09. Full-year EPS also revised up 16 vs 7 down. This positive earnings momentum contrasts with the negative analyst action.

Firm Track Record — Citigroup

Citigroup accuracy: 55% on 4355 calls | avg return: 4.9%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Citigroup has a 43% accuracy rate on 7 REGN calls, with an average return of 3.8% — below the average. Leerink is 50% on 2 calls with a -23.7% average return, the worst among all firms. The best performer is UBS (67% accuracy on 6 calls, +5.1% return); the worst by accuracy is RBC Capital (33% on 18 calls, -8.9%). Both downgrading firms are among the lowest in accuracy on this name.

Earnings Estimates

Next earnings: Jul 30, 2026

Cross-Platform Signals

Insider sales are small ($10k by CFO Ryan in April/May, $38k by director Zoghbi in February) and likely routine; no informative cluster. Congressional: Rep. Khanna bought $1k‑$15k in April — negligible. Institutional actions are mixed: Two Sigma trimmed 40% and Renaissance near-exited (‑97%), but Norges Bank initiated a $1B market position and Sound Shore added 53%. Short interest is not available. Overall, the downgrade divergence with still‑positive institutional buying and upward EPS revisions, reducing the joint signal reliability of the bearish signal.

Documents Analyzed

Report based on filing metadata.

US Market Status